

## CONFIRMATION OF THE DEVELOPMENT POTENTIAL OF AMOÉBA IN COSMETICS

### Significant results of the study carried out on 30 patients by the Institut d'Expertise Clinique

**Chassieu (France), June 10, 2024 – 5:45pm - AMOÉBA (FR0011051598 - ALMIB), an industrial greentech specialised in the treatment of microbiological risk, developing a biocontrol agent for the protection of plants in agriculture and a range of cosmetic ingredients, announces that it has received the results of the clinical study confirming the interest of using its ingredient in cosmetic as a skin care product.**

In October 2023, following tests of its ingredient on artificial skin which showed excellent results, Amoéba announced the launch of a major new application in the field of cosmetics ([see press release of October 16, 2023](#)).

An initial clinical study was carried out by the Institut d'Expertise Clinique on 30 volunteers (half-face, n=60) in March and April 2024. This study confirmed the benefits of using our ingredient in skin care cosmetics, with 'statistically significant' results justifying the following claims:

- 'improved dermis thickness'.
- 'restoring effect on the superficial dermis'.
- 'improvement in skin density'.
- 'improved dermal texture'.

Amoéba has also obtained the inclusion of this active ingredient on the **INCI** list (International Nomenclature for Cosmetic Ingredients), paving the way for marketing and the search for commercial partnerships without any further authorization being required.

The skincare market is estimated to be worth 200 billion dollars in 2023, with expected annual growth of 6% until 2030 (*source: McKinsey - The beauty market in 2023*).

Amoéba's management will have the opportunity to present its strategy on June 12 in Paris at the annual *Portzamparc BNP Paribas Group Mid & Small Caps Conference*. The presentation used for this event will be available online on the company's website at the latest by 7pm on Tuesday June 11.

---

## **About AMOÉBA:**

Founded in 2010, Amoéba is a greentech based in Chassieu (Lyon, France) with the ambition to become a major player for the treatment of microbiological risk in the water, crop protection and cosmetic sectors.


Based on the natural properties of a unique, exclusively patented, microorganism, the only one of its kind in the world, our biological solutions offer a viable alternative to the chemical products that are widely used in the industry today. Amoéba is currently focused on the global biocontrol market for plant protection and the cosmetics market. As the market release of phytosanitary products is subject to local regulatory approvals, the Company has completed the regulatory processes required and in 2022 obtained approval for its active substance in the United States and its recommendation for approval in Europe, issued by the Austrian authority. As the cosmetic application does not require prior approval from a relevant authority in Europe and the United States, the party responsible for bringing the formulated cosmetic product to market must carry out a self-assessment of its safety.

Amoéba is listed on Euronext Growth. The Company is a member of the BPI Excellence network and is eligible for the PEA-PME scheme. For more information, please visit [www.amoeba-nature.com](http://www.amoeba-nature.com).

## **Contacts:**

### **Amoéba**

Jean-François Doucet  
Chief Executive Officer


 +33 (0)4 26 69 16 00

 [jf.doucet@amoeba-nature.com](mailto:jf.doucet@amoeba-nature.com)

### **Calyptus**

*Investor & Press Relations*

Nicolas Hélin / Mathieu Calleux

 +33 (0)1 53 65 37 90 / 91

 [amoeba@calyptus.net](mailto:amoeba@calyptus.net)

## **Disclaimer**

*This press release contains certain forward-looking statements concerning AMOÉBA which are based on its own assumptions and estimates and on information that is currently available to us. However, AMOÉBA gives no assurance that the estimates contained in such forward-looking statements will be verified, with these estimates subject to numerous risks, including the risks set forth in AMOÉBA's universal registration document filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on April 29, 2024 under number D24-0352 and available on the AMOÉBA website ([www.amoeba-nature.com](http://www.amoeba-nature.com)). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOÉBA or not currently considered material by AMOÉBA. The occurrence of all or part of such risks could cause AMOÉBA's actual results, financial conditions, performance, or achievements to be materially different from such forward-looking statements.*